##ANALYSISTYPE=CFDNA
##PIPELINE=megSAP 0.2-654-gee5830f0
##CREATION_DATE=2021-08-05
##FILTER=Clustered_Variant=Clustered variants
##FILTER=Error=Alternative counts inside the expected error rate distribution
##FILTER=FDR=no description available
##FILTER=Fisher_Strand=Strand bias based on fisher test
##FILTER=LC_Downstream=Low complexity region (5bps) downstream. ≥ 80% of bases show the same nucleotide  or tandem of ≥ 3 equal nucleotides in a row
##FILTER=LC_Upstream=Low complexity region (5bps) upstream. ≥ 80% of bases show the same nucleotide or tandem of ≥ 3 equal nucleotides in a row
##FILTER=Low_AC=Less than defined minimum of alternative counts
##FILTER=Low_Complexity=no description available
##FILTER=low_conf_region=Variant marked as 'low_conf_region'.
##FILTER=Low_COV=Low coverage
##FILTER=Low_qual_pos=Position enriched with too many low quality bases
##FILTER=off-target=Variant marked as 'off-target'.
##FILTER=PASS=Passed filter
##FILTER=Strand_imbalanced=All alternative reads found in only one strand
##FILTER=Variant_Contamination=no description available
##FILTER=Variant_contamination=Reads supporting other alleles outside of the error rate distribution
##SAMPLE=<ID=DXcf000001_01,Gender=n/a,ExternalSampleName=cfDNA,IsTumor=yes,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=n/a>
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - variant quality (QUAL), depth (DP), allele frequency (AF), mean mapping quality of alternate allele (MQM), probability of strand bias for alternate bases as phred score (SAP), probability of allele ballance as phred score (ABP)
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=coding_and_splicing_refseq=Coding and splicing details based on RefSeq (Gene, RefSeq id, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=regulatory=Regulatory consequence details.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in 1000 genomes project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous counts and hemizygous counts of gnomAD project (genome data).
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=Sift=Sift effect prediction and score for each transcript: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen=PolyPhen (humVar) effect prediction and score for each transcript: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=fathmm-MKL=fathmm-MKL score (for coding/non-coding regions). Deleterious threshold > 0.5.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 10-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=MaxEntScan=MaxEntScan splicing prediction (reference bases score/alternate bases score).
##DESCRIPTION=dbscSNV=dbscSNV splicing prediction (ADA/RF score).
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=MMSplice_DeltaLogitPSI=MMsplice delta Logit PSI score: variant's effect on the exon inclusion - positive score shows higher exon inclusion, negative higher exclusion rate. A score greater than 2 or less than -2 can be considered strong.
##DESCRIPTION=MMSplice_pathogenicity=MMsplice pathogenicity score: probability of pathogenic effect of the variant on splicing
##DESCRIPTION=SpliceAI=SpliceAI prediction of splice-site variations. Probability of the variant being splice-altering (range from 0-1). The score is the maximum value of acceptor/donor gain/loss of all effected genes.
##DESCRIPTION=NGSD_som_c=Somatic variant count in the NGSD.
##DESCRIPTION=NGSD_som_p=Project names of project containing this somatic variant in the NGSD.
##DESCRIPTION=NGSD_som_vicc_interpretation=Somatic variant interpretation according VICC standard in the NGSD.
##DESCRIPTION=NGSD_som_vicc_comment=Somatic VICC interpretation comment in the NGSD.
##DESCRIPTION=NGSD_hom=Homozygous variant count in NGSD.
##DESCRIPTION=NGSD_het=Heterozygous variant count in NGSD.
##DESCRIPTION=NGSD_group=Homozygous / heterozygous variant count in NGSD with the same disease group.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validation=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Variant comments from the NGSD.
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, gnomAD o/e scores).
##DESCRIPTION=CMC_genes=Gene symbol from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_MUTATION_ID=COSV identifier of variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_disease=diseases with > 1% of samples mutated where disease = Primary site(tissue) / Primary histology / Sub-histology = Samples mutated / Samples tested = Frequency from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_DNDS_ratio=diseases with significant dn/ds ratio (q-value < 5%) from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CMC_mutation_significance=Significance tier of the variant from COSMIC Cancer Mutation Census (CMC).
##DESCRIPTION=CANCERHOTSPOTS_AA_CHANGE=Amino acid change as in original cancerhotspots.org file
##DESCRIPTION=CANCERHOTSPOTS_TOTAL_MUT=Total mutation count in cancerhotspots.org at certain amino acid position.
##DESCRIPTION=CANCERHOTSPOTS_ALT_COUNT=Count of specific amino acid alteration at same position in cancerhotspots.org.
##FILTER=low_conf_region=Low confidence region for small variant calling based on gnomAD AC0/RF filters and IMGAG trio/twin data.
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample DXcf000001_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample DXcf000001_01).
##DESCRIPTION=p-value=Uncorrected p-value
##DESCRIPTION=m_AF=Multi-UMI alternative allele fraction
##DESCRIPTION=m_REF=Multi-UMI reference-like read counts
##DESCRIPTION=m_ALT=Multi-UMI alternative read counts
##DESCRIPTION=Strand=Alleles in strands: Alternative forward, Alternative reverse, Reference forward, Reference reverse
##DESCRIPTION=Sequence context=Sequence +/- 5bp around the variant.
##DESCRIPTION=Homopolymer=Indicates if variant is in a homopolymer region.
##DESCRIPTION=somatic_classification_comment=Somatic classification comment from the NGSD.
##DESCRIPTION=somatic_classification=Somatic classification from the NGSD.
#chr	start	end	ref	obs	tumor_af	tumor_dp	p-value	Alt counts	m_AF	m_REF	m_ALT	Strand	Sequence context	Homopolymer	filter	quality	gene	variant_type	coding_and_splicing	coding_and_splicing_refseq	regulatory	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	1000g	gnomAD	gnomAD_hom_hemi	gnomAD_sub	phyloP	Sift	PolyPhen	fathmm-MKL	CADD	REVEL	MaxEntScan	dbscSNV	COSMIC	MMSplice_DeltaLogitPSI	MMSplice_pathogenicity	SpliceAI	NGSD_som_c	NGSD_som_p	NGSD_som_vicc_interpretation	NGSD_som_vicc_comment	NGSD_hom	NGSD_het	NGSD_group	classification	classification_comment	somatic_classification	somatic_classification_comment	validation	comment	gene_info	CMC_genes	CMC_MUTATION_ID	CMC_disease	CMC_DNDS_ratio	CMC_mutation_significance	CANCERHOTSPOTS_AA_CHANGE	CANCERHOTSPOTS_TOTAL_MUT	CANCERHOTSPOTS_ALT_COUNT
chr1	14155367	14155367	C	T	0.0016	5	2.40e-04	3164	0.00114	2630	3	3-2-1536-1623	CTGTACGTGTG	false	off-target	QUAL=0	PRDM2	downstream_gene	PRDM2:ENST00000235372.7:downstream_gene_variant:MODIFIER::::,PRDM2:ENST00000376048.5:downstream_gene_variant:MODIFIER::::		regulatory_region_variant:CTCF_binding_site,regulatory_region_variant:promoter_flanking_region					rs1016029259		0.0001	0,.		-1.7040			0.00,0.25	0.35								0				0	0	0 / 0							PRDM2 (inh=n/a oe_syn=1.14 oe_mis=0.90 oe_lof=0.12)								
chr1	14155402	14155402	G	A	0.7371	2288	0.00e+00	3104	0.73362	683	1881	1111-1177-391-425	CACACGTACAG	false		QUAL=0	PRDM2	downstream_gene	PRDM2:ENST00000235372.7:downstream_gene_variant:MODIFIER::::,PRDM2:ENST00000376048.5:downstream_gene_variant:MODIFIER::::		regulatory_region_variant:CTCF_binding_site,regulatory_region_variant:promoter_flanking_region,TF_binding_site_variant					rs7520386	0.4872	0.5419	4616,.		-1.5870			0.00,0.19	0.59								0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							PRDM2 (inh=n/a oe_syn=1.14 oe_mis=0.90 oe_lof=0.12)								
chr2	106738835	106738835	A	G	0.4887	1142	0.00e+00	2337	0.49284	956	929	589-553-626-569	CAGAGATAAGA	false		QUAL=0	UXS1	intron	UXS1:ENST00000283148.7:intron_variant:MODIFIER:intron9/14:c.759+591T>C::,UXS1:ENST00000409032.1:intron_variant:MODIFIER:intron4/9:c.240+591T>C::,UXS1:ENST00000409501.3:intron_variant:MODIFIER:intron9/14:c.744+591T>C::,UXS1:ENST00000428048.2:intron_variant:MODIFIER:intron3/5:c.276+591T>C::,UXS1:ENST00000540130.1:intron_variant:MODIFIER:intron8/13:c.573+591T>C::	UXS1:NM_001253875.1:intron_variant:MODIFIER:intron9/14:c.759+591T>C::,UXS1:NM_001253876.1:intron_variant:MODIFIER:intron4/9:c.240+591T>C::,UXS1:NM_025076.4:intron_variant:MODIFIER:intron9/14:c.744+591T>C::,UXS1:NR_045607.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/13:n.793+591T>C::					MIRc (SINE/MIR)	rs10185531	0.4946	0.4534	3142,.		-1.0160			0.00,0.07	1.66							0.01	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							UXS1 (inh=n/a oe_syn=1.05 oe_mis=0.62 oe_lof=0.35)								
chr2	106738881	106738881	G	A	0.2137	616	0.00e+00	2882	0.20734	1858	486	390-226-1362-904	CAGCAGCACAG	false	off-target	QUAL=0	UXS1	intron	UXS1:ENST00000283148.7:intron_variant:MODIFIER:intron9/14:c.759+545C>T::,UXS1:ENST00000409032.1:intron_variant:MODIFIER:intron4/9:c.240+545C>T::,UXS1:ENST00000409501.3:intron_variant:MODIFIER:intron9/14:c.744+545C>T::,UXS1:ENST00000428048.2:intron_variant:MODIFIER:intron3/5:c.276+545C>T::,UXS1:ENST00000540130.1:intron_variant:MODIFIER:intron8/13:c.573+545C>T::	UXS1:NM_001253875.1:intron_variant:MODIFIER:intron9/14:c.759+545C>T::,UXS1:NM_001253876.1:intron_variant:MODIFIER:intron4/9:c.240+545C>T::,UXS1:NM_025076.4:intron_variant:MODIFIER:intron9/14:c.744+545C>T::,UXS1:NR_045607.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron8/13:n.793+545C>T::					MIRc (SINE/MIR)						0.3540			0.04,0.11	1.86							0	0				0	0	0 / 0							UXS1 (inh=n/a oe_syn=1.05 oe_mis=0.62 oe_lof=0.35)								
chr2	182413238	182413238	C	T	0.4795	1330	0.00e+00	2774	0.47672	1169	1065	687-643-778-666	AGATACAGGTT	false	off-target	QUAL=0	CERKL	intron	CERKL:ENST00000339098.5:intron_variant:MODIFIER:intron9/13:c.1211+34G>A::,CERKL:ENST00000374969.2:intron_variant:MODIFIER:intron5/9:c.794+34G>A::,CERKL:ENST00000374970.2:intron_variant:MODIFIER:intron6/10:c.926+34G>A::,CERKL:ENST00000409440.3:intron_variant:MODIFIER:intron8/12:c.1079+34G>A::,CERKL:ENST00000410087.3:intron_variant:MODIFIER:intron8/12:c.1133+34G>A::	CERKL:NM_001030311.2:intron_variant:MODIFIER:intron9/13:c.1211+34G>A::,CERKL:NM_001030312.2:intron_variant:MODIFIER:intron5/9:c.794+34G>A::,CERKL:NM_001030313.2:intron_variant:MODIFIER:intron6/10:c.926+34G>A::,CERKL:NM_001160277.1:intron_variant:MODIFIER:intron8/12:c.1079+34G>A::,CERKL:NM_201548.5:intron_variant:MODIFIER:intron8/12:c.1133+34G>A::,CERKL:NR_027689.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron6/10:n.1038+34G>A::,CERKL:NR_027690.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron7/11:n.1170+34G>A::		608381 [GENE=CERKL PHENOS=Retinitis pigmentosa 26,608380];				rs72883670	0.1721	0.1682	506,.	0.2316,0.2191,0.2172,0.1165,0.0557	-8.2480			0.00,0.05	0.08					0.029	0.1959	0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							CERKL (inh=AR oe_syn=0.98 oe_mis=1.04 oe_lof=1.16)								
chr3	178936091	178936091	G	A	0.0192	60	1.50e-11	3125	0.01886	2497	48	31-29-1517-1547	TCACTGAGCAG	false		QUAL=0	PIK3CA	missense	PIK3CA:ENST00000263967.3:missense_variant:MODERATE:exon10/21:c.1633G>A:p.Glu545Lys:PF00613 [Phosphoinositide 3-kinase family accessory domain (PIK domain)]	PIK3CA:NM_006218.4:missense_variant:MODERATE:exon10/21:c.1633G>A:p.Glu545Lys:		171834 [GENE=PIK3CA PHENOS=Ovarian cancer,somatic,167000/Colorectal cancer,somatic,114500/CLAPO syndrome,somatic,613089/Cowden syndrome 5,615108/Hepatocellular carcinoma,somatic,114550/Breast cancer,somatic,114480/Macrodactyly,somatic,155500/Keratosis,seborrheic,somatic,182000/Gastric cancer,somatic,613659/Megalencephaly-capillary malformation-polymicrogyria syndrome,somatic,602501/Nevus,epidermal,somatic,162900/CLOVE syndrome,somatic,612918/Nonsmall cell lung cancer,somatic,211980];	13655 [pathogenic/likely pathogenic DISEASE=Hepatocellular carcinoma,Abnormality of cardiovascular system morphology,Pancreatic adenocarcinoma,Transitional cell carcinoma of the bladder,Neoplasm of stomach,Breast neoplasm,Brainstem glioma,Carcinoma of esophagus,Renal cell carcinoma, papillary, 1,Malignant melanoma of skin,Lung adenocarcinoma,Small cell lung carcinoma,Non-small cell lung cancer,Squamous cell lung carcinoma,Neoplasm of brain,Seborrheic keratosis,Sarcoma,Neoplasm of ovary,Nasopharyngeal Neoplasms,Neoplasm of the large intestine,Carcinoma of colon,Carcinoma of gallbladder,Breast adenocarcinoma,Adenocarcinoma of stomach,Adenocarcinoma of prostate,Gallbladder cancer,Ovarian Serous Cystadenocarcinoma,Uterine Carcinosarcoma,Squamous cell carcinoma of the head and neck,Megalencephaly-capillary malformation-polymicrogyria syndrome,Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi,Glioblastoma,Neoplasm of uterine cervix,Papillary renal cell carcinoma, sporadic,Malignant neoplasm of body of uterus,OVARIAN CANCER, EPITHELIAL, SOMATIC,PIK3CA related overgrowth spectrum,not provided];	CM126692 [CLASS=DM MUT=ALT PHEN="Megalencephaly-capillary malformation" GENE=PIK3CA];		rs104886003		0.0001		0.0000,0.0000,0.0000,0.0001,0.0000	9.4770	D(0.02)	D(0.91)	0.97,0.98	30.00	0.65			COSV55873239,COSV55878227	-0.2089	0.1015	0	37	PATHO_Somatic,SomaticAndTreatment,Vak-Heilversuche,eMed-HCC	ONCOGENIC		0	0	0 / 0							PIK3CA (inh=AR+AD oe_syn=0.78 oe_mis=0.34 oe_lof=0.05)	PIK3CA	COSV55873239	stomach/carcinoma/adenocarcinoma=51/3303=1.54%;endometrium/carcinoma/mixed_serous_and_endometrioid_carcinoma=4/85=4.71%;penis/carcinoma/squamous_cell_carcinoma=8/185=4.32%;breast/carcinoma/ER-PR-HER-positive_carcinoma=7/55=12.73%;soft_tissue/Overgrowth_syndrome/CLOVES_syndrome=7/47=14.89%;ovary/germ_cell_tumour/teratoma=13/55=23.64%;vulva/carcinoma/squamous_cell_carcinoma=11/125=8.8%;breast/carcinoma/ER-positive_carcinoma=128/1587=8.07%;ovary/carcinoma/endometrioid_carcinoma=7/326=2.15%;breast/carcinoma/hormone_receptor-positive_carcinoma=27/328=8.23%;vulva/in_situ_neoplasm/vulvar_intraepithelial_neoplasia=5/11=45.45%;breast/carcinoma/ductolobular_carcinoma=15/132=11.36%;cervix/carcinoma/endocervical_adenocarcinoma=6/62=9.68%;skin/other/seborrhoeic_keratosis=4/259=1.54%;cervix/carcinoma/small_cell_carcinoma=4/18=22.22%;breast/carcinoma_in_situ/ductal_carcinoma_in_situ=8/612=1.31%;cervix/carcinoma/adenocarcinoma=9/309=2.91%;cervix/in_situ_neoplasm/cervical_intraepithelial_neoplasia_Grade_III=6/290=2.07%;penis/carcinoma/NS=4/28=14.29%;breast/carcinoma/luminal_B_carcinoma=5/86=5.81%;gastrointestinal_tract_(site_indeterminate)/carcinoma/adenocarcinoma=7/477=1.47%;thyroid/carcinoma/anaplastic_carcinoma=13/862=1.51%;cervix/carcinoma/squamous_cell_carcinoma=83/1021=8.13%;large_intestine/carcinoma/adenocarcinoma=708/20968=3.38%;oesophagus/carcinoma/adenocarcinoma=9/815=1.1%;breast/carcinoma/basal_(triple-negative)_carcinoma=43/932=4.61%;breast/carcinoma/lobular_carcinoma=51/604=8.44%;oesophagus/carcinoma/NS=11/386=2.85%;oesophagus/carcinoma/squamous_cell_carcinoma=52/2556=2.03%;stomach/carcinoma/NS=6/559=1.07%;urinary_tract/carcinoma/transitional_cell_carcinoma=147/1805=8.14%;biliary_tract/carcinoma/NS=8/318=2.52%;salivary_gland/carcinoma/salivary_duct_carcinoma=13/160=8.13%;stomach/carcinoma/diffuse_adenocarcinoma=6/202=2.97%;upper_aerodigestive_tract/carcinoma/NS=7/369=1.9%;lung/carcinoma/NS=7/318=2.2%;breast/carcinoma/ER-PR-positive_carcinoma=28/656=4.27%;large_intestine/carcinoma/squamous_cell_carcinoma=20/215=9.3%;breast/carcinoma/NS=346/9998=3.46%;lung/carcinoma/squamous_cell_carcinoma=55/2832=1.94%;upper_aerodigestive_tract/carcinoma/nasopharyngeal_carcinoma=13/657=1.98%;ovary/carcinoma/clear_cell_carcinoma=24/763=3.15%;upper_aerodigestive_tract/carcinoma/squamous_cell_carcinoma=130/3681=3.53%;central_nervous_system/glioma/oligodendroglioma_Grade_III=6/202=2.97%;breast/carcinoma/ductal_carcinoma=205/5021=4.08%;urinary_tract/carcinoma/NS=53/818=6.48%;breast/carcinoma/luminal_NS_carcinoma=28/254=11.02%;endometrium/carcinoma/endometrioid_carcinoma=43/1964=2.19%;stomach/carcinoma/intestinal_adenocarcinoma=6/311=1.93%	cervical=1.21e-47;glioma=7.08e-08;breast=1.04e-96;colon=5.32e-71;NSCLC=6.07e-30;bladder=6.95e-26;gastric=3.17e-27;HNSCC=2.01e-40;endometrioid=1.99e-27	1			
chr4	154809707	154809707	G	C	0.2309	769	0.00e+00	3331	0.23527	2090	643	414-355-1257-1305	AGACAGAGAGT	false		QUAL=0		intergenic	::intergenic_variant:MODIFIER::::	::intergenic_variant:MODIFIER::::						rs6535964	0.4547	0.4671	3478,.		0.2700			0.11,0.27	4.88								0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)															
chr4	169663615	169663615	T	G	0.4826	1426	0.00e+00	2955	0.47953	1246	1148	694-732-762-767	TAAAGTGTTAT	false	Clustered_Variant	QUAL=0	PALLD	intron	PALLD:ENST00000261509.6:intron_variant:MODIFIER:intron10/20:c.1964+30541T>G::,PALLD:ENST00000335742.7:intron_variant:MODIFIER:intron10/20:c.818+30541T>G::,PALLD:ENST00000505667.1:intron_variant:MODIFIER:intron10/21:c.1964+30541T>G::,PALLD:ENST00000512127.1:intron_variant:MODIFIER:intron9/18:c.818+30541T>G::	PALLD:NM_001166108.2:intron_variant:MODIFIER:intron10/21:c.1964+30541T>G::,PALLD:NM_001166109.2:intron_variant:MODIFIER:intron9/18:c.818+30541T>G::,PALLD:NM_016081.4:intron_variant:MODIFIER:intron10/20:c.1964+30541T>G::	regulatory_region_variant:promoter_flanking_region	608092 [GENE=PALLD PHENOS=Pancreatic cancer,susceptibility to,1,606856,Autosomal dominant];				rs6811238	0.5585	0.5220	4249,.		-0.0370			0.08,0.16	2.68							0.01	2	PATHO_Somatic			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							PALLD (inh=AD oe_syn=0.91 oe_mis=0.90 oe_lof=0.35)								
chr6	152697706	152697706	C	T	0.2356	704	0.00e+00	2988	0.22980	1897	566	348-356-1096-1188	GGTGACGCAAA	false		QUAL=0	SYNE1	intron	SYNE1:ENST00000265368.4:intron_variant:MODIFIER:intron57/145:c.9147-13G>A::,SYNE1:ENST00000341594.5:intron_variant:MODIFIER:intron60/146:c.9264-13G>A::,SYNE1:ENST00000367255.5:intron_variant:MODIFIER:intron57/145:c.9147-13G>A::,SYNE1:ENST00000423061.1:intron_variant:MODIFIER:intron57/145:c.9168-13G>A::,SYNE1:ENST00000448038.1:intron_variant:MODIFIER:intron58/146:c.9168-13G>A::	SYNE1:NM_033071.3:intron_variant:MODIFIER:intron57/145:c.9168-13G>A::,SYNE1:NM_182961.4:intron_variant:MODIFIER:intron57/145:c.9147-13G>A::		608441 [GENE=SYNE1 PHENOS=Arthrogryposis multiplex congenita 3,myogenic type,618484,Autosomal recessive/Spinocerebellar ataxia,autosomal recessive 8,610743,Autosomal recessive/Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998,Autosomal dominant];	262202 [benign DISEASE=Spinocerebellar ataxia, autosomal recessive 8,Emery-Dreifuss muscular dystrophy 4, autosomal dominant,not specified];			rs214955		0.5040	3955,.	0.5521,0.5071,0.5533,0.4656,0.5980	1.4780			0.00,0.14	6.39		7.58>6.65			-0.2816	0.9414		1	SomaticAndTreatment			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							SYNE1 (inh=AR+AD oe_syn=1.05 oe_mis=1.01 oe_lof=0.37), SYNE1-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)								
chr7	55242465	55242479	GGAATTAAGAGAAGC	-	0.0064	28	2.95e-08	4364	0.00622	3513	22	13-15-2172-2164	TATCAAGGAAT	false		QUAL=0	EGFR	inframe_deletion,intron	EGFR:ENST00000275493.2:inframe_deletion:MODERATE:exon19/28:c.2235_2249del:p.Glu746_Ala750del:PF07714 [Protein tyrosine kinase],EGFR:ENST00000442591.1:intron_variant:MODIFIER:intron17/17:c.*28+1844_*28+1858del::,EGFR:ENST00000454757.2:inframe_deletion:MODERATE:exon19/28:c.2076_2090del:p.Glu693_Ala697del:PF07714 [Protein tyrosine kinase],EGFR:ENST00000455089.1:inframe_deletion:MODERATE:exon18/26:c.2100_2114del:p.Glu701_Ala705del:PF07714 [Protein tyrosine kinase]	EGFR:NM_001346897.2:inframe_deletion:MODERATE:exon18/26:c.2100_2114del:p.Glu701_Ala705del:,EGFR:NM_001346898.2:inframe_deletion:MODERATE:exon19/27:c.2235_2249del:p.Glu746_Ala750del:,EGFR:NM_001346899.1:inframe_deletion:MODERATE:exon18/27:c.2100_2114del:p.Glu701_Ala705del:,EGFR:NM_001346900.2:inframe_deletion:MODERATE:exon19/28:c.2076_2090del:p.Glu693_Ala697del:,EGFR:NM_001346941.2:inframe_deletion:MODERATE:exon13/22:c.1434_1448del:p.Glu479_Ala483del:,EGFR:NM_005228.5:inframe_deletion:MODERATE:exon19/28:c.2235_2249del:p.Glu746_Ala750del:		131550 [GENE=EGFR PHENOS=Inflammatory skin and bowel disease,neonatal,2,616069,Autosomal recessive/Nonsmall cell lung cancer,response to tyrosine kinase inhibitor in,211980,Somatic mutation,Autosomal dominant/Adenocarcinoma of lung,response to tyrosine kinase inhibitor in,211980,Somatic mutation,Autosomal dominant/Nonsmall cell lung cancer,susceptibility to,211980,Somatic mutation,Autosomal dominant];	163343 [drug response DISEASE=Tyrosine kinase inhibitor response];			rs121913421					9.7630				22.10				COSV51765119	-0.5868	0.2016	0.06	0				0	0	0 / 0							EGFR (inh=AR oe_syn=1.13 oe_mis=0.80 oe_lof=0.23), EGFR-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)	EGFR	COSV51765119	lung/carcinoma/adenocarcinoma=524/49215=1.06%;lung/carcinoma/mixed_adenosquamous_carcinoma=25/746=3.35%;lung/carcinoma/non_small_cell_carcinoma=533/35864=1.49%;lung/other/hyperplasia=10/138=7.25%;lung/carcinoma/bronchioloalveolar_adenocarcinoma=30/1081=2.78%		Other			
chr7	55248998	55248998	-	TGGCCAGCG	0.0046	21	8.74e-06	4573	0.00399	3744	15	17-4-2202-2347	ACGTGATGGCC	false	Variant_Contamination	QUAL=0	EGFR,EGFR-AS1	inframe_insertion,non_coding_transcript_exon,intron	EGFR:ENST00000275493.2:inframe_insertion:MODERATE:exon20/28:c.2300_2308dup:p.Ala767_Val769dup:PF07714 [Protein tyrosine kinase],EGFR-AS1:ENST00000442411.1:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.1242_1250dup::,EGFR:ENST00000442591.1:intron_variant:MODIFIER:intron17/17:c.*28+8381_*28+8389dup::,EGFR:ENST00000454757.2:inframe_insertion:MODERATE:exon20/28:c.2141_2149dup:p.Ala714_Val716dup:PF07714 [Protein tyrosine kinase],EGFR:ENST00000455089.1:inframe_insertion:MODERATE:exon19/26:c.2165_2173dup:p.Ala722_Val724dup:PF07714 [Protein tyrosine kinase]	EGFR:NM_001346897.2:inframe_insertion:MODERATE:exon19/26:c.2165_2173dup:p.Ala722_Val724dup:,EGFR:NM_001346898.2:inframe_insertion:MODERATE:exon20/27:c.2300_2308dup:p.Ala767_Val769dup:,EGFR:NM_001346899.1:inframe_insertion:MODERATE:exon19/27:c.2165_2173dup:p.Ala722_Val724dup:,EGFR:NM_001346900.2:inframe_insertion:MODERATE:exon20/28:c.2141_2149dup:p.Ala714_Val716dup:,EGFR:NM_001346941.2:inframe_insertion:MODERATE:exon14/22:c.1499_1507dup:p.Ala500_Val502dup:,EGFR:NM_005228.5:inframe_insertion:MODERATE:exon20/28:c.2300_2308dup:p.Ala767_Val769dup:,EGFR-AS1:NR_047551.1:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.1257_1265dup::	regulatory_region_variant:promoter_flanking_region,TF_binding_site_variant	131550 [GENE=EGFR PHENOS=Inflammatory skin and bowel disease,neonatal,2,616069,Autosomal recessive/Nonsmall cell lung cancer,response to tyrosine kinase inhibitor in,211980,Somatic mutation,Autosomal dominant/Adenocarcinoma of lung,response to tyrosine kinase inhibitor in,211980,Somatic mutation,Autosomal dominant/Nonsmall cell lung cancer,susceptibility to,211980,Somatic mutation,Autosomal dominant];	177678 [drug response DISEASE=Tyrosine kinase inhibitor response];			rs727504263														0.0149	0.87	0.01	0				0	0	0 / 0							EGFR (inh=AR oe_syn=1.13 oe_mis=0.80 oe_lof=0.23), EGFR-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a)								
chr7	124392512	124392512	C	T	0.4428	1885	0.00e+00	4257	0.44326	1928	1535	998-887-1268-1104	CTTTACATATG	false		QUAL=0	GPR37	intron	GPR37:ENST00000303921.2:intron_variant:MODIFIER:intron1/1:c.1024-5115G>A::	GPR37:NM_005302.5:intron_variant:MODIFIER:intron1/1:c.1024-5115G>A::	regulatory_region_variant:enhancer					rs2267708	0.4936	0.4686	3477,.		-1.6590			0.00,0.06	0.72							0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							GPR37 (inh=n/a oe_syn=0.91 oe_mis=0.88 oe_lof=0.45)								
chr7	137029838	137029838	T	C	0.4352	2240	0.00e+00	5147	0.43979	2233	1753	1223-1017-1550-1357	ACTTCTGTGTG	false		QUAL=0	AC078842.3	non_coding_transcript_exon	AC078842.3:ENST00000438969.2:non_coding_transcript_exon_variant:MODIFIER:exon4/4:n.391A>G::							rs321198	0.5635	0.5630	4991,.		-1.5030			0.00,0.07	5.85					0.1023	0.9169		3	PATHO_Somatic			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							PTN (inh=n/a oe_syn=0.89 oe_mis=0.65 oe_lof=0.47)								
chr7	150439500	150439500	C	T	0.4506	2270	0.00e+00	5038	0.45315	2241	1857	1117-1153-1386-1382	CAGGCCGATAC	false		QUAL=0	GIMAP5	synonymous	GIMAP5:ENST00000358647.3:synonymous_variant:LOW:exon3/3:c.273C>T:p.Ala91=:PF04548 [AIG1 family]	GIMAP1-GIMAP5:NM_001199577.1:synonymous_variant:LOW:exon6/6:c.885C>T:p.Ala295=:,GIMAP1-GIMAP5:NM_001303630.1:synonymous_variant:LOW:exon5/5:c.501C>T:p.Ala167=:,GIMAP5:NM_018384.4:synonymous_variant:LOW:exon3/3:c.273C>T:p.Ala91=:	regulatory_region_variant:promoter_flanking_region					rs759011	0.3900	0.3966	2694,.	0.5573,0.2281,0.2679,0.3094,0.3772	-2.0610			0.04,0.18	1.26					-0.0102	0.9887	0.02	2	I16R041,eMed-HCC			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							GIMAP5 (inh=n/a oe_syn=1.18 oe_mis=1.12 oe_lof=0.90)	GIMAP5	COSV57529710			Other			
chr8	28411072	28411072	T	C	0.7473	2173	0.00e+00	2908	0.75042	590	1774	1037-1136-345-390	TGAAGTTTTCC	false	Low_Complexity	QUAL=0	FZD3	intron	FZD3:ENST00000240093.3:intron_variant:MODIFIER:intron6/7:c.1553+1804T>C::,FZD3:ENST00000537916.1:intron_variant:MODIFIER:intron5/6:c.1553+1804T>C::	FZD3:NM_017412.4:intron_variant:MODIFIER:intron6/7:c.1553+1804T>C::,FZD3:NM_145866.1:intron_variant:MODIFIER:intron5/6:c.1553+1804T>C::						rs10092491		0.5808	5363,.		-0.2140			0.00,0.05	2.50							0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							FZD3 (inh=n/a oe_syn=0.97 oe_mis=0.62 oe_lof=0.37)								
chr9	131023505	131023505	T	C	0.3731	1496	1.16e-57	4010	0.36708	2088	1211	803-693-1266-1247	ACTCATGCTAC	false		QUAL=0	GOLGA2	missense	GOLGA2:ENST00000421699.2:missense_variant:MODERATE:exon16/26:c.1285A>G:p.Met429Val:PF15070 [Putative golgin subfamily A member 2-like protein 5],GOLGA2:ENST00000609374.1:missense_variant:MODERATE:exon16/26:c.1249A>G:p.Met417Val:PF15070 [Putative golgin subfamily A member 2-like protein 5]	GOLGA2:NM_001366244.1:missense_variant:MODERATE:exon17/27:c.1330A>G:p.Met444Val:,GOLGA2:NM_001366246.1:missense_variant:MODERATE:exon16/26:c.1249A>G:p.Met417Val:,GOLGA2:NM_004486.5:missense_variant:MODERATE:exon16/26:c.1249A>G:p.Met417Val:						rs16912752	0.0941	0.0910	462,.	0.3146,0.0149,0.0001,0.0011,0.0005	-4.1660	T(0.82),T(0.86)	B(0.00),B(0.00)	0.02,0.15	0.04	0.04				-0.1281	0.9566	0.01	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							GOLGA2 (inh=n/a oe_syn=0.92 oe_mis=0.89 oe_lof=0.18)								
chr9	131023516	131023516	T	-	0.0015	6	1.30e-02	3968	0.00031	3275	1	2-4-2041-1921	CATTCCTTCTC	false	FDR;off-target	QUAL=0	GOLGA2	frameshift	GOLGA2:ENST00000421699.2:frameshift_variant:HIGH:exon16/26:c.1274del:p.Lys425ArgfsTer5:PF15070 [Putative golgin subfamily A member 2-like protein 5],GOLGA2:ENST00000609374.1:frameshift_variant:HIGH:exon16/26:c.1238del:p.Lys413ArgfsTer5:PF15070 [Putative golgin subfamily A member 2-like protein 5]	GOLGA2:NM_001366244.1:frameshift_variant:HIGH:exon17/27:c.1319del:p.Lys440ArgfsTer5:,GOLGA2:NM_001366246.1:frameshift_variant:HIGH:exon16/26:c.1238del:p.Lys413ArgfsTer5:,GOLGA2:NM_004486.5:frameshift_variant:HIGH:exon16/26:c.1238del:p.Lys413ArgfsTer5:											2.0150									-0.3333	0.9557	0.01	0				0	0	0 / 0							GOLGA2 (inh=n/a oe_syn=0.92 oe_mis=0.89 oe_lof=0.18)								
chr9	131186783	131186783	C	T	0.3904	1766	0.00e+00	4524	0.38647	2286	1440	863-903-1353-1405	CCTTGCATCCC	false		QUAL=0	CERCAM	missense	CERCAM:ENST00000372838.4:missense_variant:MODERATE:exon5/13:c.656C>T:p.Ala219Val:,CERCAM:ENST00000372842.1:missense_variant:MODERATE:exon6/14:c.422C>T:p.Ala141Val:	CERCAM:NM_001286760.1:missense_variant:MODERATE:exon5/13:c.422C>T:p.Ala141Val:,CERCAM:NM_016174.5:missense_variant:MODERATE:exon5/13:c.656C>T:p.Ala219Val:						rs61732491	0.0545	0.0510	130,.	0.1822,0.0106,0.0000,0.0006,0.0004	5.1290	T(0.66),T(0.69)	B(0.00),B(0.00)	0.03,0.22	15.48	0.21				-0.0195	0.1563	0.01	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							CERCAM (inh=n/a oe_syn=0.91 oe_mis=0.98 oe_lof=0.52)								
chr10	73121913	73121913	A	G	0.7760	3101	0.00e+00	3996	0.77658	727	2527	1515-1586-458-437	CCGCCATCTGC	false	off-target	QUAL=0	SLC29A3	missense	SLC29A3:ENST00000373189.5:missense_variant:MODERATE:exon6/6:c.976A>G:p.Ile326Val:PF01733 [Nucleoside transporter]	SLC29A3:NM_001174098.1:3_prime_UTR_variant:MODIFIER:exon6/6:c.*205A>G::,SLC29A3:NM_001363518.1:missense_variant:MODERATE:exon6/6:c.742A>G:p.Ile248Val:,SLC29A3:NM_018344.6:missense_variant:MODERATE:exon6/6:c.976A>G:p.Ile326Val:,SLC29A3:NR_033413.1:non_coding_transcript_exon_variant:MODIFIER:exon5/5:n.950A>G::,SLC29A3:NR_033414.1:non_coding_transcript_exon_variant:MODIFIER:exon4/4:n.723A>G::		612373 [GENE=SLC29A3 PHENOS=Histiocytosis-lymphadenopathy plus syndrome,602782,Autosomal recessive];	130347 [benign DISEASE=Histiocytosis-lymphadenopathy plus syndrome,not specified];			rs2487068	0.7927	0.8744	12044,.	0.9271,0.6409,0.7129,0.8707,0.7788	-0.5910	T(1.00)	B(0.03)	0.03,0.16	0.01	0.03				0.017	0.8641	0.01	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							SLC29A3 (inh=AR oe_syn=1.17 oe_mis=1.08 oe_lof=0.82)	SLC29A3	COSV64386549			Other			
chr10	73121945	73121945	T	C	1.0000	4003	0.00e+00	4003	1.00000	0	3275	1928-2075-0-0	AAGGGTTCGGG	false		QUAL=0	SLC29A3	synonymous	SLC29A3:ENST00000373189.5:synonymous_variant:LOW:exon6/6:c.1008T>C:p.Gly336=:PF01733 [Nucleoside transporter]	SLC29A3:NM_001174098.1:3_prime_UTR_variant:MODIFIER:exon6/6:c.*237T>C::,SLC29A3:NM_001363518.1:synonymous_variant:LOW:exon6/6:c.774T>C:p.Gly258=:,SLC29A3:NM_018344.6:synonymous_variant:LOW:exon6/6:c.1008T>C:p.Gly336=:,SLC29A3:NR_033413.1:non_coding_transcript_exon_variant:MODIFIER:exon5/5:n.982T>C::,SLC29A3:NR_033414.1:non_coding_transcript_exon_variant:MODIFIER:exon4/4:n.755T>C::		612373 [GENE=SLC29A3 PHENOS=Histiocytosis-lymphadenopathy plus syndrome,602782,Autosomal recessive];	130337 [benign DISEASE=Histiocytosis-lymphadenopathy plus syndrome,not specified];			rs1084004		0.8454	11319,.	0.7543,0.6258,0.7225,0.9122,0.7725	0.3230			0.02,0.22	2.15					0.0046	0.8638	0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							SLC29A3 (inh=AR oe_syn=1.17 oe_mis=1.08 oe_lof=0.82)	SLC29A3	COSV64385266			Other			
chr11	64201639	64201639	C	T	0.7262	2247	0.00e+00	3094	0.72394	686	1799	1269-978-466-381	GGTGACCCATA	false		QUAL=0		intergenic	::intergenic_variant:MODIFIER::::	::intergenic_variant:MODIFIER::::					Eutr16 (DNA?/hAT-Tip100?)	rs550840	0.5549	0.5044	4011,.		0.5060			0.02,0.11	4.41								0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)															
chr11	115207144	115207144	C	G	0.2387	635	0.00e+00	2660	0.23360	1624	495	349-286-1139-885	ACTTTCAATTT	false	off-target	QUAL=0	CADM1,AP000462.3	intron,intron&non_coding_transcript	CADM1:ENST00000331581.6:intron_variant:MODIFIER:intron1/11:c.125-96004G>C::,CADM1:ENST00000452722.3:intron_variant:MODIFIER:intron1/9:c.125-96004G>C::,CADM1:ENST00000536727.1:intron_variant:MODIFIER:intron1/10:c.125-96004G>C::,CADM1:ENST00000537058.1:intron_variant:MODIFIER:intron1/10:c.125-96004G>C::,CADM1:ENST00000542447.2:intron_variant:MODIFIER:intron1/8:c.125-96004G>C::,AP000462.3:ENST00000545593.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron1/1:n.42+2807C>G::	CADM1:NM_001098517.2:intron_variant:MODIFIER:intron1/8:c.125-96004G>C::,CADM1:NM_001301043.2:intron_variant:MODIFIER:intron1/11:c.125-96004G>C::,CADM1:NM_001301044.2:intron_variant:MODIFIER:intron1/10:c.125-96004G>C::,CADM1:NM_001301045.2:intron_variant:MODIFIER:intron1/10:c.125-96004G>C::,CADM1:NM_014333.4:intron_variant:MODIFIER:intron1/9:c.125-96004G>C::,LOC105369509:NR_135108.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron1/1:n.42+2807C>G::						rs75460798	0.0156	0.0209	4,.		-2.5530			0.01,0.13	10.69							0	0				0	0	0 / 0							CADM1 (inh=n/a oe_syn=1.14 oe_mis=0.67 oe_lof=0.19)								
chr11	115207176	115207176	C	G	1.0000	2684	0.00e+00	2684	1.00000	0	2144	1267-1417-0-0	ACCGACTGCCA	false		QUAL=0	CADM1,AP000462.3	intron,intron&non_coding_transcript	CADM1:ENST00000331581.6:intron_variant:MODIFIER:intron1/11:c.125-96036G>C::,CADM1:ENST00000452722.3:intron_variant:MODIFIER:intron1/9:c.125-96036G>C::,CADM1:ENST00000536727.1:intron_variant:MODIFIER:intron1/10:c.125-96036G>C::,CADM1:ENST00000537058.1:intron_variant:MODIFIER:intron1/10:c.125-96036G>C::,CADM1:ENST00000542447.2:intron_variant:MODIFIER:intron1/8:c.125-96036G>C::,AP000462.3:ENST00000545593.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron1/1:n.42+2839C>G::	CADM1:NM_001098517.2:intron_variant:MODIFIER:intron1/8:c.125-96036G>C::,CADM1:NM_001301043.2:intron_variant:MODIFIER:intron1/11:c.125-96036G>C::,CADM1:NM_001301044.2:intron_variant:MODIFIER:intron1/10:c.125-96036G>C::,CADM1:NM_001301045.2:intron_variant:MODIFIER:intron1/10:c.125-96036G>C::,CADM1:NM_014333.4:intron_variant:MODIFIER:intron1/9:c.125-96036G>C::,LOC105369509:NR_135108.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron1/1:n.42+2839C>G::						rs10488710		0.6267	6233,.		-0.8860			0.00,0.06	0.14							0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							CADM1 (inh=n/a oe_syn=1.14 oe_mis=0.67 oe_lof=0.19)								
chr13	100038233	100038233	A	G	0.6178	1311	0.00e+00	2122	0.61409	663	1055	630-681-431-380	TATCCAGAGTT	false		QUAL=0	UBAC2	3'UTR	UBAC2:ENST00000376440.2:3_prime_UTR_variant:MODIFIER:exon7/7:c.*644A>G::	UBAC2:NM_001144072.2:3_prime_UTR_variant:MODIFIER:exon9/9:c.*644A>G::,UBAC2:NM_177967.4:3_prime_UTR_variant:MODIFIER:exon7/7:c.*644A>G::,UBAC2:NR_026644.2:non_coding_transcript_exon_variant:MODIFIER:exon9/9:n.2362A>G::						rs1058083	0.6112	0.6358	6386,.		-0.1080			0.02,0.14	11.25					0.028	0.9153		0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							UBAC2 (inh=n/a oe_syn=0.89 oe_mis=0.68 oe_lof=0.37)								
chr13	100038271	100038271	A	T	0.6144	1359	0.00e+00	2212	0.61327	688	1091	701-658-454-399	TGGAGAAGAAC	false	off-target	QUAL=0	UBAC2	3'UTR	UBAC2:ENST00000376440.2:3_prime_UTR_variant:MODIFIER:exon7/7:c.*682A>T::	UBAC2:NM_001144072.2:3_prime_UTR_variant:MODIFIER:exon9/9:c.*682A>T::,UBAC2:NM_177967.4:3_prime_UTR_variant:MODIFIER:exon7/7:c.*682A>T::,UBAC2:NR_026644.2:non_coding_transcript_exon_variant:MODIFIER:exon9/9:n.2400A>T::						rs701537	0.6118	0.6374	6415,.		0.7150			0.14,0.16	1.97					-0.0532	0.9139		0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							UBAC2 (inh=n/a oe_syn=0.89 oe_mis=0.68 oe_lof=0.37)								
chr14	62750546	62750546	C	T	0.7958	2720	0.00e+00	3418	0.79135	574	2177	1343-1377-346-351	ATTCTCAGAAG	false	Clustered_Variant	QUAL=0		intergenic	::intergenic_variant:MODIFIER::::	::intergenic_variant:MODIFIER::::						rs7151786	0.5735	0.5322	4495,.		-1.0360			0.01,0.11	7.64								0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)															
chr15	79816157	79816157	G	A	0.4569	1419	0.00e+00	3106	0.46120	1361	1165	612-807-867-820	CCAGTGTCCAC	false		QUAL=0		intergenic	::intergenic_variant:MODIFIER::::	::intergenic_variant:MODIFIER::::						rs955665	0.5709	0.5365	4534,.		1.1120			0.04,0.13	3.53								0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)															
chr17	48433958	48433958	T	C	0.4737	1655	0.00e+00	3494	0.46963	1493	1322	830-825-891-948	CTGTATGGCAG	false		QUAL=0	XYLT2	synonymous	XYLT2:ENST00000017003.2:synonymous_variant:LOW:exon8/11:c.1569T>C:p.Tyr523=:PF12529 [Xylosyltransferase C terminal],XYLT2:ENST00000507602.1:synonymous_variant:LOW:exon8/10:c.1569T>C:p.Tyr523=:PF12529 [Xylosyltransferase C terminal]	XYLT2:NM_022167.4:synonymous_variant:LOW:exon8/11:c.1569T>C:p.Tyr523=:,XYLT2:NR_110010.2:non_coding_transcript_exon_variant:MODIFIER:exon8/10:n.1584T>C::		608125 [GENE=XYLT2 PHENOS=Pseudoxanthoma elasticum,modifier of severity of,264800,Autosomal recessive/Spondyloocular syndrome,605822,Autosomal recessive];		CM064363 [CLASS=DP MUT=ALT PHEN="Organ involvement in PXE association with" GENE=XYLT2];		rs4794136	0.3826	0.4445	3189,.	0.5018,0.6120,0.1044,0.4746,0.3086	-2.4070			0.19,0.91	8.75					0.0603	0.0781	0.02	2	Leuk,eMed-HCC			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							XYLT2 (inh=AR oe_syn=1.02 oe_mis=0.75 oe_lof=0.17)	XYLT2	COSV50017488			Other			
chr17	80461935	80461935	C	T	0.4951	1528	1.41e-56	3086	0.49623	1269	1250	802-726-827-731	CTCCCCGGCTG	false	Low_Complexity;Clustered_Variant	QUAL=0		intergenic	::intergenic_variant:MODIFIER::::	::intergenic_variant:MODIFIER::::						rs8078417	0.3095	0.2934	1388,.		0.0160			0.01,0.14	1.04								0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)															
chr18	9749879	9749879	G	A	0.4936	1653	0.00e+00	3349	0.49706	1369	1353	852-801-851-845	TATGGGTTGCC	false		QUAL=0	RAB31	intron	RAB31:ENST00000578921.1:intron_variant:MODIFIER:intron1/6:c.40-25396G>A::	RAB31:NM_006868.4:intron_variant:MODIFIER:intron1/6:c.40-25396G>A::						rs9951171	0.4455	0.4413	3063,.		0.2360			0.05,0.16	5.46							0	4	PATHO_Somatic			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							RAB31 (inh=n/a oe_syn=0.62 oe_mis=0.65 oe_lof=0.57)								
chr19	47177913	47177913	A	G	1.0000	3240	0.00e+00	3240	1.00000	0	2666	1571-1669-0-0	AGCGCACGTCG	false	Clustered_Variant	QUAL=0	PRKD2,DACT3-AS1	missense,intron&non_coding_transcript	PRKD2:ENST00000291281.4:missense_variant:MODERATE:exon18/18:c.2504T>C:p.Val835Ala:,PRKD2:ENST00000433867.1:missense_variant:MODERATE:exon19/19:c.2504T>C:p.Val835Ala:,DACT3-AS1:ENST00000525008.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron2/2:n.189-2484A>G::,PRKD2:ENST00000595515.1:missense_variant:MODERATE:exon19/19:c.2534T>C:p.Val845Ala:,PRKD2:ENST00000600194.1:missense_variant:MODERATE:exon17/17:c.2033T>C:p.Val678Ala:,PRKD2:ENST00000601806.1:missense_variant:MODERATE:exon19/19:c.2033T>C:p.Val678Ala:	PRKD2:NM_001079880.1:synonymous_variant:LOW:exon19/19:c.2504T>C:p.Ala835=:,PRKD2:NM_001079881.1:synonymous_variant:LOW:exon19/19:c.2504T>C:p.Ala835=:,PRKD2:NM_001079882.1:synonymous_variant:LOW:exon17/17:c.2033T>C:p.Ala678=:,PRKD2:NM_016457.4:synonymous_variant:LOW:exon18/18:c.2504T>C:p.Ala835=:,DACT3-AS1:NR_040042.1:intron_variant&non_coding_transcript_variant:MODIFIER:intron2/2:n.189-2484A>G::						rs314665	1.0000	0.9996	15633,.	0.9996,1.0000,1.0000,0.9992,1.0000	3.9570	T(1.00),T(1.00), ,T(1.00),T(1.00),T(1.00)	B(0.00),B(0.00), ,B(0.00),B(0.00),B(0.00)	0.16,0.87	20.50	0.11				-0.0329	0.9464	0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							DACT3-AS1 (inh=n/a oe_syn=n/a oe_mis=n/a oe_lof=n/a), PRKD2 (inh=n/a oe_syn=1.03 oe_mis=0.57 oe_lof=0.07)	PRKD2	COSV52188687	lung/carcinoma/non_small_cell_carcinoma=6/6=100%;lung/carcinoma/squamous_cell_carcinoma=43/50=86%;lung/carcinoma/large_cell_carcinoma=5/11=45.45%;lung/carcinoma/adenocarcinoma=33/39=84.62%		Other			
chr19	49905029	49905029	T	C	0.2405	755	0.00e+00	3139	0.24218	1937	619	354-401-1180-1204	CTTTGTCCTAC	false		QUAL=0	KASH5	intron	KASH5:ENST00000447857.3:intron_variant:MODIFIER:intron9/19:c.798+2265T>C::	CCDC155:NM_144688.5:intron_variant:MODIFIER:intron9/19:c.798+2265T>C::						rs8105430	0.5290	0.5213	4237,.		-1.0400			0.03,0.62	11.08							0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							KASH5 (inh=n/a oe_syn=0.77 oe_mis=0.81 oe_lof=0.55)								
chr20	62172269	62172269	C	A	0.5814	2464	0.00e+00	4238	0.58099	1472	2041	1121-1343-844-930	GAGCACGTAGA	false	off-target	QUAL=0	SRMS	missense	SRMS:ENST00000217188.1:missense_variant:MODERATE:exon8/8:c.1369G>T:p.Val457Leu:PF07714 [Protein tyrosine kinase]	SRMS:NM_080823.3:missense_variant:MODERATE:exon8/8:c.1369G>T:p.Val457Leu:	regulatory_region_variant:CTCF_binding_site					rs310654	0.1599	0.1422	751,.	0.4161,0.0493,0.0318,0.0499,0.0316	-4.2600	T(0.30)	B(0.01)	0.18,0.12	0.42	0.06				-0.1227	0.9171	0	0				n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)							PTK6 (inh=n/a oe_syn=1.08 oe_mis=0.93 oe_lof=0.92), SRMS (inh=n/a oe_syn=0.93 oe_mis=1.00 oe_lof=1.03)	SRMS	COSV53916588			Other			
chr22	33559508	33559508	T	A	0.9989	2820	0.00e+00	2823	1.00000	0	2295	1392-1428-0-3	CACCCTTGTAG	false		QUAL=0	RP1-302D9.3	upstream_gene	RP1-302D9.3:ENST00000434741.1:upstream_gene_variant:MODIFIER::::	::intergenic_variant:MODIFIER::::						rs987640		0.4574	3207,.		-0.0570			0.00,0.06	4.62					-0.0013	0.9089		2	PATHO_Somatic			n/a (AF>5%)	n/a (AF>5%)	n/a (AF>5%)															
